CLOs on the Move

Berg Pharma

www.bergpharma.com

 
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bergpharma.com
  • 500 Old Connecticut Path
    Framingham, MA USA 01701
  • Phone: 617.588.0083

Executives

Name Title Contact Details

Similar Companies

Cytheris

Cytheris is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

F H Ayer Manufacturing Company

F H Ayer Manufacturing Company is a Chicago Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monticello Drug Company

Monticello Drug Company is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

Odyssey Behavioral Healthcare

Odyssey Behavioral Health consists of a growing portfolio of quality behavioral health facilities with evidence-based clinical care.